Sun Pharma Q1 Net Profit Rises 27% on India Growth; US Sales Decline
Sun Pharmaceutical Industries reported a 27% year-on-year rise in consolidated net profit to approximately Rs 2,895 crore for Q1 FY27, with revenue increasing about 10% to over Rs 15,183 crore. Growth was driven by a 16% increase in India formulations sales, which accounted for 36.1% of total sales. US formulations sales declined nearly 10%, impacted by generics weakness, though innovative medicines showed growth. EBITDA rose 2.7% to Rs 4,418 crore, while EBITDA margin contracted to 28.9%. The company noted acquisition-related expenses linked to Organon Co., with the deal expected to close in early 2027.
First-hand measurement across 8 sources
We measured how 8 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (64/100). Lens Score 33/100.
Outlets measured: businessstandard, businessstandard, businessstandard, news18, thefinancialexpress, businessstandard, economictimes, freepressjournal. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
freepressjournal broke this story on 31 Jul, 09:12 am. Other outlets followed.